Stoke Therapeutics (STOK) Net Cash Flow (2018 - 2026)
Stoke Therapeutics (STOK) posted quarterly Net Cash Flow of $74.4 million for Q1 2026, down 49.3% year-over-year from $146.8 million in Q1 2025, and up 8911.99% quarter-over-quarter from $826000.0 in Q4 2025.
Stoke Therapeutics (STOK) Net Cash Flow (2018 - 2026) Analysis & Trends
Stoke Therapeutics' Net Cash Flow history runs 9 years deep, the most recent figure standing at $74.4 million for Q1 2026.
- In Q1 2026, Net Cash Flow fell 49.3% year-over-year to $74.4 million; the TTM figure through Mar 2026 stood at -$116.2 million (down 220.5% YoY), while the FY2025 annual figure was -$43.8 million, up 30.67% from the prior year.
- Net Cash Flow for Q1 2026 stood at $74.4 million, up from $826000.0 in the prior quarter.
- The five-year high for Net Cash Flow was $146.8 million in Q1 2025, with the low at -$173.3 million in Q2 2025.
- The 5-year median for Net Cash Flow is $160000.0 (2022), against an average of $818588.2.
- The sharpest annual moves came in 2024 and 2025: Net Cash Flow tumbled 1986.41% in 2024, then jumped 1241.69% in 2025.
- Stoke Therapeutics' Net Cash Flow stood at $160000.0 in 2022, then surged by 815.62% to $1.5 million in 2023, then plunged by 1588.46% to -$21.8 million in 2024, then jumped by 103.79% to $826000.0 in 2025, then soared by 8911.99% to $74.4 million in 2026.
- Business Quant data shows STOK's Net Cash Flow at $74.4 million in Q1 2026, $826000.0 in Q4 2025, and -$18.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 374.50 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 407.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 17.81 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 225.59 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -496,000.00 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -37.14 Mn |
| 10 | Stoke Therapeutics | 1.95 Bn | 1.66 Bn | - | -45.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -45.66 Mn |
| Jun 30, 2026 | -45.66 Mn |
| Mar 31, 2026 | 74.44 Mn |
| Mar 31, 2026 | 74.44 Mn |
| Dec 31, 2025 | 826,000.00 |
| Dec 31, 2025 | 826,000.00 |
| Sep 30, 2025 | -18.15 Mn |
| Sep 30, 2025 | -18.15 Mn |
| Jun 30, 2025 | -173.35 Mn |
| Jun 30, 2025 | -173.35 Mn |
| Mar 31, 2025 | 146.83 Mn |
| Mar 31, 2025 | 146.83 Mn |
| Dec 31, 2024 | -21.81 Mn |
| Dec 31, 2024 | -21.81 Mn |
| Sep 30, 2024 | -43.46 Mn |
| Sep 30, 2024 | -43.46 Mn |
| Jun 30, 2024 | 14.90 Mn |
| Jun 30, 2024 | 14.90 Mn |
| Mar 31, 2024 | -12.86 Mn |
| Mar 31, 2024 | -12.86 Mn |